Welcome to our dedicated page for Innovate news (Ticker: VATE), a resource for investors and traders seeking the latest updates and insights on Innovate stock.
INNOVATE Corp. (NYSE: VATE) generates news across its three reported segments: Infrastructure, Life Sciences and Spectrum. As a holding company with operating subsidiaries and equity method investments, its disclosures cover developments in structural steel construction, medical technology, aesthetic devices and over-the-air broadcasting.
News about the Infrastructure segment often focuses on DBM Global Inc., a family of companies providing integrated steel construction services. Coverage includes project activity, revenue by segment, backlog levels and cash dividends paid by DBM Global to its stockholders, with INNOVATE identified as the largest stockholder.
In Life Sciences, INNOVATE’s news highlights regulatory and commercial milestones at portfolio companies such as MediBeacon Inc. and R2 Technologies, Inc. Releases have detailed U.S. Food and Drug Administration approval for MediBeacon’s TGFR system, approvals in China for the Transdermal GFR System and Lumitrace injection, and growth in R2’s Glacial Skin CryoAesthetics platforms and global system sales.
The Spectrum segment generates updates on broadcasting operations, including revenue trends, new network launches and datacasting initiatives using ATSC 3.0 technology. INNOVATE has reported on the launch of ATSC 3.0 stations for a large mobile carrier and efforts to expand reach with additional networks.
Investors and followers of VATE can use this news feed to review INNOVATE’s quarterly earnings releases, Form 8-K announcements, refinancing transactions, segment performance commentary and major events at DBM Global, MediBeacon and R2. Regular updates provide a consolidated view of how developments in each segment contribute to the overall INNOVATE portfolio.
INNOVATE Corp. (NYSE: VATE) plans to release its Q1 2022 financial results on May 4, 2022, after market close. A live earnings conference call will take place at 4:30 p.m. ET on the same day, discussing these results, operations, and strategies. Participants can join via domestic dial-in at 1-844-826-3033 or toll/international at 1-412-317-5185. A replay will be available after the call until May 18, 2022. INNOVATE operates across infrastructure, life sciences, and spectrum sectors with approximately 3,902 employees.
INNOVATE Corp. (NYSE: VATE) reported a remarkable fourth quarter in 2021 with revenue soaring to $394.8 million, a 121.8% increase from the previous year. The Infrastructure segment, particularly DBM Global, led this growth with record revenues of $383.4 million. Despite a net loss of $5.2 million, down from $7.1 million in Q4 2020, Adjusted EBITDA also rose significantly to $22.1 million. The company maintains a strong backlog of $1,580.9 million, indicating robust future potential.
INNOVATE Corp. (NYSE: VATE) will announce its fourth quarter and full year 2021 financial results on March 9, 2022, after market close. An earnings conference call will follow at 4:30 p.m. ET, discussing the results, operations, and strategic direction. Interested parties can access the live call via INNOVATE’s Investor Relations website. For those unable to attend, a replay will be available post-call until March 23, 2022. INNOVATE operates in key sectors including Infrastructure, Life Sciences, and Spectrum.
INNOVATE Corp. (NYSE: VATE) has announced the successful completion of 21 new broadcast stations by its Spectrum segment, HC2 Broadcasting Holdings. This expansion adds 12 new designated market areas (DMAs) to their coverage, bringing the total to nearly 250 stations across the U.S. Broadcasting now operates in over 106 TV markets, including 34 of the top 35. This strategic growth is positioned to enhance service to over-the-air customers and provide robust distribution platforms for content providers, ultimately driving value for stakeholders.
INNOVATE Corp. (NYSE: VATE) reported Q3 2021 results with consolidated revenue of $394.8 million, a 131.6% increase from $170.5 million in Q3 2020. However, the company faced a net loss of $213.0 million, drastically up from $17.7 million the previous year. Key segments showed notable performance: Infrastructure secured $383.0 million in revenue, maintaining a $1.6 billion backlog, while Life Sciences achieved a crucial FDA approval for Glacial Rx®, and Spectrum reported its fourth positive EBITDA quarter.
INNOVATE Corp. (NYSE: VATE) announced its third quarter 2021 financial results release scheduled for November 4, 2021, after market close. The company will host a conference call at 4:30 p.m. ET the same day to discuss the results, operations, and strategy. Interested parties can access the live call via INNOVATE’s Investor Relations website. Dial-in details include a domestic number at 1-800-763-5545 and an international number at 1-212-231-2901. Replay instructions will be available post-call.
INNOVATE Corp. (NYSE: VATE) announced that its subsidiary R2 Technologies’ Glacial Rx is the first and only Class II dermal cooling system FDA-cleared for dermabrasion, scar revision, and tattoo removal. The clearance marks a significant milestone following Glacial Rx's commercial launch in March 2021, indicating its unique position in the aesthetics industry. R2's CEO highlighted the innovative effort behind this achievement, noting that it led to a new FDA product code. The company continues to receive orders from aesthetic providers, further enhancing its market presence.
INNOVATE Corp. (NYSE: VATE) has successfully completed its name change from HC2 Holdings, effective September 20, 2021. The new name reflects the Company's commitment to growth in key sectors such as Infrastructure, Life Sciences, and Spectrum. With the transition, trading under the new ticker symbol 'VATE' has commenced on the New York Stock Exchange.
The rebranding aims to position INNOVATE as a leader in the new economy, focusing on innovative growth strategies. Shareholders do not need to take any action regarding the name change.